drug:orforglipron

Updates from MariTide & Orforglipron research

MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.

chemical:semaglutide

After two months, Novo Nordisk and HIMS part ways

Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.

category:news

Preserving muscle: GLP1s with Bimagrumab

We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.

company:novo-nordisk

Novo Nordisk patent protections lapse in Canada

Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.

category:news

A challenge to Eli Lilly's Tirzepatide patent

Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.

drug:eloralinitide

Amylin, with and without GLP1: Eloralinitide

We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.

category:side-effects

Ozempic is not likely to directly enlarge the male appendage.

A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.

company:eli-lilly

Eli Lilly's big Summer 2025 update

We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.

research

Semaglutide vs Tirzepatide (Clinical trial)

Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.

company:roche

Roche and Carmot's GLP1 pipeline

We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.

category:news

A new risk: Kidney Cancer

New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.

malady:addiction

GLP1s vs. Addiction, a quick review

We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.

drug:retatrutide

An update on Retatrutide (May 2025)

We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.

category:benefits

GLP1s lower inflammation, Psoriasis, AND increase fertility?

We look into the anti-inflammatory effects of GLP1s and their effects on issues like psoriasis and infertility.

politics

GLP1s and Tariffs, the story so far

We take a look at the various movements in GLP1 policy by the Trump administration, so far.

drug:wegovy

Wegovy in pill form is coming

Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.

drug:nimacimab

Boosting Tirzepatide with Nimacimab

Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.

company:eli-lilly

Eli Lilly suing GLP1 compounders & related companies

Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.

company:pfizer

Pfizer ends development of oral GLP1 Danuglipron

Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.

drug:mounjaro

Mounjaro's India launch

Eli Lilly's Mounjaro launches in India

category:news

Oral pill Orforglipron delivers stellar results in Phase 3 Trial

Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!

politics

Trump revokes planned Medicare/Medicaid coverage for GLP1s

Trump administration revokes the planned Medicare Part D coverage for anti-obesity GLP1 drugs.

politics

2025 Trump Tariffs on Pharmaceutical Imports

Trump announces soon-to-be tariffs on pharmaceutical imports, we dig into how much Novo Nordisk and Eli Lilly could be affected.

Once a year GLP1? Exploring Semaglutide implants

GLP1 implants that are administered once or twice a year and deliver consistent Semaglutide, powered by Vivani Medical's NanoPortal technology.

category:news

Hims pivots to branded Tirzepatide, generic Liraglutide

Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.